Sermonix Pharmaceuticals Convenes Scientific Advisory Board

July 23, 2015

Sermonix Pharmaceuticals to Present Three Lasofoxifene Papers and One Poster at the North American Menopause Society Meeting

September 16, 2015

Sermonix Pharmaceuticals Shares Study Results at the North American Menopause Society

September 30, 2015

Sermonix Receives Two Awards at the North American Menopause Society Annual Meeting

October 7, 2015

Sermonix to Present Scientific Poster Comparing Investigational Drug Lasofoxifene to Raloxifene at American Society for Bone and Mineral Research Annual Meeting

October 9, 2015

Sermonix Pharmaceuticals to Give Two Lasofoxifene Presentations at International Society for the Study of Women’s Sexual Health Meeting

February 10, 2016

Sermonix Pharmaceuticals to Give Lasofoxifene Oral Presentation at World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Disease

March 31, 2016

Sermonix Pharmaceuticals Announces Dr. Anthony H. Wild as Board Chairman and Investor

May 3, 2016

Sermonix Pharmaceuticals Convenes Breast Cancer Oncology Steering Committee to Explore Utility of Lasofoxifene

August 3, 2016

Sermonix Pharmaceuticals’ Exploratory Analysis on Orgasm Frequency With SERMs Is Named Featured Poster for 2016 North American Menopause Society Annual Meeting

September 16, 2016

Sermonix Pharmaceuticals to Present Poster on Physician Perceptions of Menopausal Serms at San Antonio Breast Cancer Symposium

November 28, 2016

Sermonix Pharmaceuticals Signs Exclusive Licensing Agreement to Further Explore Lasofoxifene For Breast Cancer Treatment

December 7, 2016

Sermonix Pharmaceuticals Secures Worldwide Rights to Oral Lasofoxifene From Ligand Pharmaceuticals, Expanding From U.S., Japan

March 3, 2017